✨ Free AI Report
VolitionRx Limited: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research VolitionRx Limited
Company Research

VolitionRx Limited: Business Overview, Financials & Competitive Analysis

VolitionRx Limited is a multi-national epigenetics company that develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The comp...

Analyst-debate audio for VolitionRx Limited

AskCyborg analysts argue the bull and bear cases for VolitionRx Limited across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

Early-stage diagnostic company with transformative technology seeking scale through major pharmaceutical partnerships, but...

Read the full analyst-debate transcript →
Industry Diagnostic Medical Devices & Epigenetics Biotech
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest VolitionRx Limited Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

VolitionRx Limited Overview

Pro stress-test →

VolitionRx Limited is a multi-national epigenetics company that develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company utilizes proprietary nucleosomics technology to create non-invasive diagnostic solutions that aim to provide early disease detection.

Strategic Profile

Pro stress-test →

2025 is a pivotal year for Volition as it focuses on commercializing its Nu.Q® platform in the human diagnostics market, with confidential discussions with more than ten companies, where the combined market value of seven of these companies exceeds $600 billion. The company's business model is based on a dual-path strategy: developing high-impact diagnostic tests for both human and animal health, and monetizing its intellectual property through strategic licensing or collaboration deals with key industry partners.

Competitive Landscape

Pro stress-test →

Volition has initiated commercial discussions with significant players in the diagnostic space for both human and animal health out-licensing opportunities in large markets such as sepsis and oncology liquid biopsy. Primary competitors in the blood-based cancer diagnostics space include Guardant Health, Foundation Medicine, and other liquid biopsy developers, though Volition's nucleosomics approach and dual-market strategy (human and veterinary) provide differentiation.

Industry Context

VolitionRx Limited operates in Diagnostic Medical Devices & Epigenetics Biotech.

Key facts

Headquarters: Henderson, Nevada, United States · Employees: 85 · Revenue: $0.25M (Q1 2025)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on VolitionRx Limited.

  • First commercial sales of CE-marked Nu.Q® NETs product drive 44% revenue growth.
  • Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Business Review of 2025 issued highlighting commercialization progress
  • November 2025First commercial sale of Nu.Q® Cancer assay announced
  • +2 moreTrack every material event for VolitionRx Limited as it happens. Explore monitoring →
Get alerted when VolitionRx Limited has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Liquid Biopsy TestingBlood-based cancer detection and monitoring platform→Genomic Cancer TestingComprehensive genomic profiling for cancer diagnostics→Veterinary DiagnosticsAnimal health diagnostics and imaging solutions→

Compare VolitionRx Limited with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

VolitionRx Limited operates in Diagnostic Medical Devices & Epigenetics Biotech. See how the rest of the sector scores on the Cyborg framework.

Browse Diagnostic Medical Devices & Epigenetics Biotech research →
NEW · MCP server

Ask your AI assistant about VolitionRx Limited

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare VolitionRx Limited and its top competitor on Cyborg Score”
“What did VolitionRx Limited do this quarter?”
“Is VolitionRx Limited a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does VolitionRx Limited do?+
VolitionRx Limited is a multi-national epigenetics company that develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The comp...
What is VolitionRx Limited's Cyborg Score?+
VolitionRx Limited has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are VolitionRx Limited's main competitors?+
Named competitors include Liquid Biopsy Testing, Genomic Cancer Testing, Veterinary Diagnostics. The full competitive landscape is in the AskCyborg report.
How can I get the full VolitionRx Limited research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the VolitionRx Limited research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track VolitionRx Limited over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.